Roles and Responsibilities: To act as the Commercial Asset Lead for the pipeline-in-a-product, FB102, and its' related projects: provide strategic leadership to the FB102 Asset Team (a multifunctional team of regional-based professionals) specific to life cycle management, product strategy and FB102 activities, to maximize the value of the medicine over its entire lifecycle; Collaborate across various areas of expertise with key global stakeholders including [but not limited to]: Market Access, Medical Affairs, Patient Advocacy, Health Economics and Outcomes Research, Clinical Science, CMC, Global Regulatory, Business Development, and Scientific Communications, to ensure that the pre-launch indication plans are implemented globally and in the key regions and/or affiliates; Work closely in collaboration with the FB102 Asset Clinical Development team to ensure strategic alignment of clinical development and manufacturing plans; Mobilize the organization to ensure regional launch readiness and implementation of various global launch and/or pre-launch activities; Serve as the primary point of contact with the regional General Managers, to consistently ensure that unique market needs and insights are gathered and appropriately addressed; To ensure proper staffing of the FB102 commercial team and key sub-teams including the FB102 global marketing and commercial new product planning team for pipeline indications for FB102; Skills and Competencies: In-depth knowledge and proven track record in setting strategy and launching therapeutic innovation in the major pharmaceutical markets. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases.